Although this study only focused on EGFR mutations and therapies in NSCLC, future studies can explore a similar approach for EGFR mutant cancers or other GFs driving oncogenic transformations to improve the current therapies (Figure 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.